Trial Profile
Safety and Efficacy of Low Molecular Weight Heparin for 72 Hours Followed by Dabigatran for the Treatment of Acute Intermediate-Risk Pulmonary Embolism
Status:
Discontinued
Phase of Trial:
Phase IV
Latest Information Update: 01 Dec 2021
Price :
$35
*
At a glance
- Drugs Dabigatran etexilate (Primary) ; Low molecular weight heparins
- Indications Pulmonary embolism
- Focus Adverse reactions; Therapeutic Use
- Acronyms PEITHO-2
- 08 Nov 2020 This trial has been completed in Netherlands, according to European Clinical Trials Database record.
- 28 Apr 2020 This trial has been completed in Austria according to European Clinical Trials Database record.
- 23 Mar 2020 This trial has been completed in Belgium according to European Clinical Trials Database record.